Tag: lung cancer diagnostic and screening market key players

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Lung Cancer Diagnostic And Screening Market Revenue Growth Supported By A CAGR Of 4.03% Through 2030

The market dedicated to the diagnosis and screening of lung cancer has experienced considerable expansion lately. Projections indicate a rise from $2.56 billion in 202

The market for lung cancer diagnostics and screening is poised for substantial expansion over the coming years, with projections indicating a rise to $4.04 billion by 2030, driven by a compound annual growth rate of 9.6%. This anticipated growth trajectory is fueled by several key factors, including the broadening reach of nationwide lung cancer screening programs, a greater acceptance of low-dose CT screening technologies, an escalating demand for both biomarker and blood-based testing solutions, increased financial commitments within the healthcare sector towards oncology diagnostics, and enhanced accessibility to diagnostic imaging facilities. Furthermore, prominent developments anticipated during this forecast period encompass a rise in the implementation of early lung cancer screening initiatives, increased utilization of sophisticated imaging and biomarker assays, a concentrated effort on screening high-risk demographic groups, the further development and deployment of non-invasive diagnostic methods, and a growing trend toward the combined use of various diagnostic approaches.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

Lung Cancer Diagnostic And Screening Market Growth Drivers And Industry Catalysts

The accelerating incidence of lung cancer is poised to be a significant catalyst for the expansion of the lung cancer diagnostic and screening market. Lung cancer, characterized by the uncontrolled multiplication of aberrant cells within the lung tissue, manifests with distressing symptoms like persistent coughing, chest discomfort, and labored breathing. Detection and screening methods play a crucial role in the early identification of this condition, employing diverse diagnostic procedures such as incisional biopsies and bronchoscopies. To illustrate, data from January 2023, as reported by the American Cancer Society, a governmental entity in the U.S., indicated an estimated 238,340 new lung cancer diagnoses across the United States, comprising 117,550 males and 120,790 females. Additionally, this report detailed approximately 127,070 fatalities attributed to lung cancer, with 67,160 deaths occurring among men and 59,910 among women. Consequently, the escalating occurrence of lung cancer is a primary driver fueling the growth trajectory of the market dedicated to its diagnosis and screening.

Lung Cancer Diagnostic And Screening Market Segment Landscape: Which Areas Lead Market Development?

The lung cancer diagnostic and screening market covered in this report is segmented –

1) By Product: Instruments, Consumables And Accessories

2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests

3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users

Subsegments:

1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems

2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Sample Collection Kits

#Lung Cancer Diagnostic And Screening Market Trends Influencing Long-Term Demand

Several key players within the lung cancer diagnostic and screening sector are concentrating their efforts on pioneering a blood-based testing solution powered by machine learning technologies, specifically whole-genome machine learning, with the overarching goals of enhancing accessibility and convenience in lung cancer screening and securing a stronger market position. The concept of whole-genome machine learning involves the implementation of sophisticated algorithms to scrutinize and interpret the complete spectrum of an organism’s genetic data, covering its entire genome. As an illustrative example, in the month of October in 2023, DELFI Diagnostics Inc., a company based in the United States and known for its work on accessible blood tests, introduced FirstLook Lung. This groundbreaking blood test leverages whole-genome machine learning to examine fragments of cell-free DNA, thereby significantly improving lung cancer screening with an impressive negative predictive value of 99.7%. Developed with the intention of integration into standard blood work procedures, this test is capable of detecting individuals who may have lung cancer, including those in the initial stages of the disease. By aiming to overcome the challenge of low participation rates in low-dose computed tomography (LDCT) screening, this innovative test seeks to contribute positively to the overall health of the population.

Lung Cancer Diagnostic And Screening Market Industry Leaders And Market Competition

Major companies operating in the lung cancer diagnostic and screening market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Oncimmune Holdings Plc, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, OncoCyte, Broncus Medical Inc.

Access The Complete Lung Cancer Diagnostic And Screening Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Lung Cancer Diagnostic And Screening Market Global Footprint: Which Region Holds Market Leadership?

North America was the largest region in the lung cancer diagnostic and screening market in 2025. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Lung Cancer Diagnostic And Screening Market Revenue Growth Supported By A CAGR Of 4.03% Through 2030

The market dedicated to the diagnosis and screening of lung cancer has experienced considerable expansion lately. Projections indicate a rise from $2.56 billion in 202

The market for lung cancer diagnostics and screening is poised for substantial expansion over the coming years, with projections indicating a rise to $4.04 billion by 2030, driven by a compound annual growth rate of 9.6%. This anticipated growth trajectory is fueled by several key factors, including the broadening reach of nationwide lung cancer screening programs, a greater acceptance of low-dose CT screening technologies, an escalating demand for both biomarker and blood-based testing solutions, increased financial commitments within the healthcare sector towards oncology diagnostics, and enhanced accessibility to diagnostic imaging facilities. Furthermore, prominent developments anticipated during this forecast period encompass a rise in the implementation of early lung cancer screening initiatives, increased utilization of sophisticated imaging and biomarker assays, a concentrated effort on screening high-risk demographic groups, the further development and deployment of non-invasive diagnostic methods, and a growing trend toward the combined use of various diagnostic approaches.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

Lung Cancer Diagnostic And Screening Market Growth Drivers And Industry Catalysts

The accelerating incidence of lung cancer is poised to be a significant catalyst for the expansion of the lung cancer diagnostic and screening market. Lung cancer, characterized by the uncontrolled multiplication of aberrant cells within the lung tissue, manifests with distressing symptoms like persistent coughing, chest discomfort, and labored breathing. Detection and screening methods play a crucial role in the early identification of this condition, employing diverse diagnostic procedures such as incisional biopsies and bronchoscopies. To illustrate, data from January 2023, as reported by the American Cancer Society, a governmental entity in the U.S., indicated an estimated 238,340 new lung cancer diagnoses across the United States, comprising 117,550 males and 120,790 females. Additionally, this report detailed approximately 127,070 fatalities attributed to lung cancer, with 67,160 deaths occurring among men and 59,910 among women. Consequently, the escalating occurrence of lung cancer is a primary driver fueling the growth trajectory of the market dedicated to its diagnosis and screening.

Lung Cancer Diagnostic And Screening Market Segment Landscape: Which Areas Lead Market Development?

The lung cancer diagnostic and screening market covered in this report is segmented –

1) By Product: Instruments, Consumables And Accessories

2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests

3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users

Subsegments:

1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems

2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Sample Collection Kits

#Lung Cancer Diagnostic And Screening Market Trends Influencing Long-Term Demand

Several key players within the lung cancer diagnostic and screening sector are concentrating their efforts on pioneering a blood-based testing solution powered by machine learning technologies, specifically whole-genome machine learning, with the overarching goals of enhancing accessibility and convenience in lung cancer screening and securing a stronger market position. The concept of whole-genome machine learning involves the implementation of sophisticated algorithms to scrutinize and interpret the complete spectrum of an organism’s genetic data, covering its entire genome. As an illustrative example, in the month of October in 2023, DELFI Diagnostics Inc., a company based in the United States and known for its work on accessible blood tests, introduced FirstLook Lung. This groundbreaking blood test leverages whole-genome machine learning to examine fragments of cell-free DNA, thereby significantly improving lung cancer screening with an impressive negative predictive value of 99.7%. Developed with the intention of integration into standard blood work procedures, this test is capable of detecting individuals who may have lung cancer, including those in the initial stages of the disease. By aiming to overcome the challenge of low participation rates in low-dose computed tomography (LDCT) screening, this innovative test seeks to contribute positively to the overall health of the population.

Lung Cancer Diagnostic And Screening Market Industry Leaders And Market Competition

Major companies operating in the lung cancer diagnostic and screening market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Oncimmune Holdings Plc, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, OncoCyte, Broncus Medical Inc.

Access The Complete Lung Cancer Diagnostic And Screening Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Lung Cancer Diagnostic And Screening Market Global Footprint: Which Region Holds Market Leadership?

North America was the largest region in the lung cancer diagnostic and screening market in 2025. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Lung Cancer Diagnostic And Screening Market Revenue Growth Supported By A CAGR Of 4.03% Through 2030

The market dedicated to the diagnosis and screening of lung cancer has experienced considerable expansion lately. Projections indicate a rise from $2.56 billion in 202

The market for lung cancer diagnostics and screening is poised for substantial expansion over the coming years, with projections indicating a rise to $4.04 billion by 2030, driven by a compound annual growth rate of 9.6%. This anticipated growth trajectory is fueled by several key factors, including the broadening reach of nationwide lung cancer screening programs, a greater acceptance of low-dose CT screening technologies, an escalating demand for both biomarker and blood-based testing solutions, increased financial commitments within the healthcare sector towards oncology diagnostics, and enhanced accessibility to diagnostic imaging facilities. Furthermore, prominent developments anticipated during this forecast period encompass a rise in the implementation of early lung cancer screening initiatives, increased utilization of sophisticated imaging and biomarker assays, a concentrated effort on screening high-risk demographic groups, the further development and deployment of non-invasive diagnostic methods, and a growing trend toward the combined use of various diagnostic approaches.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

Lung Cancer Diagnostic And Screening Market Growth Drivers And Industry Catalysts

The accelerating incidence of lung cancer is poised to be a significant catalyst for the expansion of the lung cancer diagnostic and screening market. Lung cancer, characterized by the uncontrolled multiplication of aberrant cells within the lung tissue, manifests with distressing symptoms like persistent coughing, chest discomfort, and labored breathing. Detection and screening methods play a crucial role in the early identification of this condition, employing diverse diagnostic procedures such as incisional biopsies and bronchoscopies. To illustrate, data from January 2023, as reported by the American Cancer Society, a governmental entity in the U.S., indicated an estimated 238,340 new lung cancer diagnoses across the United States, comprising 117,550 males and 120,790 females. Additionally, this report detailed approximately 127,070 fatalities attributed to lung cancer, with 67,160 deaths occurring among men and 59,910 among women. Consequently, the escalating occurrence of lung cancer is a primary driver fueling the growth trajectory of the market dedicated to its diagnosis and screening.

Lung Cancer Diagnostic And Screening Market Segment Landscape: Which Areas Lead Market Development?

The lung cancer diagnostic and screening market covered in this report is segmented –

1) By Product: Instruments, Consumables And Accessories

2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests

3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users

Subsegments:

1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems

2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Sample Collection Kits

#Lung Cancer Diagnostic And Screening Market Trends Influencing Long-Term Demand

Several key players within the lung cancer diagnostic and screening sector are concentrating their efforts on pioneering a blood-based testing solution powered by machine learning technologies, specifically whole-genome machine learning, with the overarching goals of enhancing accessibility and convenience in lung cancer screening and securing a stronger market position. The concept of whole-genome machine learning involves the implementation of sophisticated algorithms to scrutinize and interpret the complete spectrum of an organism’s genetic data, covering its entire genome. As an illustrative example, in the month of October in 2023, DELFI Diagnostics Inc., a company based in the United States and known for its work on accessible blood tests, introduced FirstLook Lung. This groundbreaking blood test leverages whole-genome machine learning to examine fragments of cell-free DNA, thereby significantly improving lung cancer screening with an impressive negative predictive value of 99.7%. Developed with the intention of integration into standard blood work procedures, this test is capable of detecting individuals who may have lung cancer, including those in the initial stages of the disease. By aiming to overcome the challenge of low participation rates in low-dose computed tomography (LDCT) screening, this innovative test seeks to contribute positively to the overall health of the population.

Lung Cancer Diagnostic And Screening Market Industry Leaders And Market Competition

Major companies operating in the lung cancer diagnostic and screening market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Oncimmune Holdings Plc, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, OncoCyte, Broncus Medical Inc.

Access The Complete Lung Cancer Diagnostic And Screening Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Lung Cancer Diagnostic And Screening Market Global Footprint: Which Region Holds Market Leadership?

North America was the largest region in the lung cancer diagnostic and screening market in 2025. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Growth In Market Value Is Anticipated For The Lung Cancer Diagnostic And Screening Market Between 2026 And 2030?

The market size for lung cancer diagnostics and screening has experienced robust expansion over recent years. Projections indicate it will expand from $2.56 billion in 2025 to reach $2.8 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.4%. This historical growth can be ascribed to several factors, including the significant prevalence of smoking-related lung cancer, the extensive adoption of chest x-ray and ct imaging, the expansion of hospital-based diagnostic infrastructure, a heightened awareness regarding early lung cancer detection, and the rise of biopsy-based diagnostic confirmation.

The market for lung cancer diagnostics and screening is anticipated to experience substantial expansion over the coming years. This market is projected to reach $4.04 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. Several factors are expected to drive this growth during the forecast period, including the broadening of national lung cancer screening programs, the wider uptake of low-dose CT screening, an increasing need for biomarker and blood-based tests, greater healthcare spending on oncology diagnostics, and enhanced availability of diagnostic imaging facilities. Key trends anticipated within this period involve the increasing embrace of early lung cancer screening initiatives, the expanded application of advanced imaging and biomarker testing, a heightened emphasis on screening high-risk demographics, the proliferation of non-invasive diagnostic methodologies, and the growing incorporation of multimodal diagnostic approaches.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

Which Drivers Are Advancing The Lung Cancer Diagnostic And Screening Market Growth?

The market for lung cancer diagnosis and screening is anticipated to expand due to the rising occurrence of lung cancer. This malignant condition, characterized by the uncontrolled spread of atypical cells in lung tissues, manifests with symptoms like coughing, chest pain, and breathing difficulties. Diagnostic and screening procedures for lung cancer enable early detection of the illness in patients through diverse tests, such as incisional biopsy and bronchoscopy. An illustrative example from January 2023, based on data from the American Cancer Society, a US-based government organization, indicated that the United States saw approximately 238,340 new cases of lung cancer (comprising 117,550 in men and 120,790 in women). Additionally, 127,070 lung cancer deaths were reported (with 67,160 affecting men and 59,910 affecting women). Consequently, the increased prevalence of lung cancer is a key factor propelling the expansion of the lung cancer diagnostic and screening market.

How Is The Lung Cancer Diagnostic And Screening Market Distributed Across Key Segments?

The lung cancer diagnostic and screening market covered in this report is segmented –

1) By Product: Instruments, Consumables And Accessories

2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests

3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users

Subsegments:

1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems

2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Sample Collection Kits

Which Trends Are Supporting The Evolution Of The Lung Cancer Diagnostic And Screening Market?

Major companies in the lung cancer diagnostic and screening market are concentrating on developing blood-based tests that utilize machine learning, such as whole-genome machine learning, to provide accessible and convenient lung cancer screening and gain a competitive edge. Whole-genome machine learning refers to the application of machine learning algorithms for analyzing and interpreting comprehensive genetic information, encompassing an organism’s entire genome. For instance, in October 2023, DELFI Diagnostics Inc., a US-based developer of accessible blood-based tests, launched FirstLook Lung, a blood test employing whole-genome machine learning to analyze cell-free DNA fragments, thereby improving lung cancer screening with a 99.7% NPV. This test, designed for routine blood work, identifies individuals with potential lung cancer, including early-stage disease. Addressing low LDCT screening uptake, the test aims to improve population health.

Which Key Players Are Active In The Lung Cancer Diagnostic And Screening Market?

Major companies operating in the lung cancer diagnostic and screening market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Oncimmune Holdings Plc, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, OncoCyte, Broncus Medical Inc.

Access The Complete Lung Cancer Diagnostic And Screening Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Which Region Commands The Largest Share Of The Lung Cancer Diagnostic And Screening Market?

North America was the largest region in the lung cancer diagnostic and screening market in 2025. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Lung Cancer Diagnostic And Screening Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12043&type=smp

Browse Through More Reports Similar to the Global Lung Cancer Diagnostic And Screening Market 2026, By The Business Research Company

Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Respiratory Disease Testing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

Lung Cancer Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Lung Cancer Diagnostic And Screening Market Expected To Reach Based On Its 2026 Value?

The lung cancer diagnostic and screening market size has experienced robust growth in recent years. Projections indicate it will expand from $2.56 billion in 2025 to $2.8 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.4%. Historically, this expansion is linked to factors such as the high incidence of smoking-related lung cancer, the broad adoption of chest x-ray and CT imaging, the expansion of hospital-based diagnostic facilities, increased recognition of the importance of early lung cancer detection, and the rise of biopsy-based diagnostic confirmation.

The market for lung cancer diagnostics and screening is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $4.04 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. Factors contributing to this growth during the projection period include the broadening of national initiatives for lung cancer screening, a rise in the uptake of low-dose CT screening, an increasing need for biomarker and blood-based tests, escalating healthcare investments directed towards oncology diagnostics, and enhanced availability of diagnostic imaging centers. Key trends expected during the forecast period encompass the increasing implementation of early lung cancer screening programs, the expanding utilization of advanced imaging and biomarker tests, a heightened emphasis on screening high-risk populations, the proliferation of non-invasive diagnostic methods, and the growing incorporation of multimodal diagnostic pathways.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

What Factors Are Contributing To The Growth Of The Lung Cancer Diagnostic And Screening Market?

The growing occurrence of lung cancer is anticipated to boost the expansion of the lung cancer diagnostic and screening market in the foreseeable future. This malignant disease, characterized by the uncontrolled spread of aberrant cells within lung tissues, presents with symptoms like coughing, chest pain, and breathing difficulties. Through various tests, including an incisional biopsy and a bronchoscopy, lung cancer diagnosis and screening facilitate the early detection of the condition in patients. Illustratively, data from the American Cancer Society, a US-based government organization, indicated that in January 2023, the United States recorded about 238,340 new instances of lung cancer (comprising 117,550 in men and 120,790 in women). Additionally, reports showed 127,070 fatalities attributed to lung cancer (with 67,160 among men and 59,910 among women). Consequently, the increased prevalence of lung cancer is a key factor propelling the expansion of the lung cancer diagnostic and screening market.

How Is Segmentation Applied In The Lung Cancer Diagnostic And Screening Market Segment Analysis?

The lung cancer diagnostic and screening market covered in this report is segmented –

1) By Product: Instruments, Consumables And Accessories

2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests

3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users

Subsegments:

1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems

2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Sample Collection Kits

What Trends Are Shaping The Future Of The Lung Cancer Diagnostic And Screening Market?

Major companies in the lung cancer diagnostic and screening market are dedicating efforts to developing a blood-based test that integrates machine learning, such as whole-genome machine learning, to deliver accessible and convenient lung cancer screening and gain a competitive edge in the sector. Whole-genome machine learning refers to the application of machine learning algorithms for analyzing and interpreting comprehensive sets of genetic data, encompassing an organism’s entire genome. For instance, in October 2023, DELFI Diagnostics Inc., a US-based developer of accessible blood-based tests, launched FirstLook Lung, a blood test utilizing whole-genome machine learning to analyze cell-free DNA fragments, thereby enhancing lung cancer screening with a 99.7% NPV. This test, designed for routine blood work, pinpoints individuals with potential lung cancer, including early-stage disease. By addressing the low uptake of LDCT screening, the test aims to improve population health.

Who Are The Companies Participating In The Lung Cancer Diagnostic And Screening Market Environment?

Major companies operating in the lung cancer diagnostic and screening market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Oncimmune Holdings Plc, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, OncoCyte, Broncus Medical Inc.

Get The Full Lung Cancer Diagnostic And Screening Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Which Region Holds The Highest Market Share In The Lung Cancer Diagnostic And Screening Market?

North America was the largest region in the lung cancer diagnostic and screening market in 2025. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Lung Cancer Diagnostic And Screening Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Browse Through More Reports Similar to the Global Lung Cancer Diagnostic And Screening Market 2026, By The Business Research Company

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Respiratory Disease Testing Market Report

https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

Lung Cancer Drugs Market Report

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Lung Cancer Diagnostic And Screening Market By The End Of 2030?

The lung cancer diagnostic and screening market size has demonstrated robust growth in recent years. It is projected to expand from $2.56 billion in 2025 to $2.8 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.4%. This historical expansion can be attributed to several factors, including the high occurrence of smoking-related lung cancer, the widespread application of chest x-ray and CT imaging, the enhancement of hospital-based diagnostic infrastructure, a heightened awareness regarding the early detection of lung cancer, and the increasing use of biopsy-based diagnostic confirmation.

The lung cancer diagnostic and screening market is projected to experience substantial expansion over the coming years. This market is anticipated to reach $4.04 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. Key factors contributing to this growth during the forecast period include the broadening of national lung cancer screening programs, the increasing uptake of low-dose CT screening, a surge in demand for biomarker and blood-based testing, escalating healthcare investments in oncology diagnostics, and enhanced availability of diagnostic imaging facilities. Prominent trends expected during this period involve the increasing embrace of early lung cancer screening initiatives, the expanding application of advanced imaging and biomarker analyses, a heightened emphasis on screening high-risk populations, the broadening of non-invasive diagnostic methodologies, and a greater integration of multimodal diagnostic approaches.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

What Drivers Are Shaping The Future Growth Of The Lung Cancer Diagnostic And Screening Market?

The growing incidence of lung cancer is projected to drive expansion within the lung cancer diagnostic and screening market in the coming years. Lung cancer is a severe illness characterized by the uncontrolled multiplication of atypical cells within lung tissues, manifesting with symptoms like persistent coughing, chest discomfort, and breathing difficulties. Early detection of lung cancer through diagnosis and screening methods, such as an incisional biopsy and a bronchoscopy, assists patients in identifying the disease promptly. As an illustration, data from January 2023, released by the American Cancer Society, a US-based government entity, indicated that the United States recorded roughly 238,340 new instances of lung cancer (comprising 117,550 in men and 120,790 in women). Additionally, 127,070 fatalities were reported due to lung cancer (with 67,160 being men and 59,910 being women). Consequently, the heightened prevalence of lung cancer is a primary factor fueling the expansion of the lung cancer diagnostic and screening market.

Which Segment Classifications Shape The Lung Cancer Diagnostic And Screening Market?

The lung cancer diagnostic and screening market covered in this report is segmented –

1) By Product: Instruments, Consumables And Accessories

2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests

3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users

Subsegments:

1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems

2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Sample Collection Kits

What Key Trends Are Influencing The Development Of The Lung Cancer Diagnostic And Screening Market?

Key companies in the lung cancer diagnostic and screening sector are concentrating on creating blood-based tests that incorporate machine learning, such as whole-genome machine learning, to offer readily available and convenient lung cancer screening and gain a market advantage. Whole-genome machine learning involves applying machine learning algorithms to examine and understand comprehensive sets of genetic data, covering an organism’s complete genome. For instance, in October 2023, DELFI Diagnostics Inc., a US-based company focused on accessible blood-based tests, launched FirstLook Lung. This blood test utilizes whole-genome machine learning to analyze cell-free DNA fragments, thereby improving lung cancer screening with a 99.7% NPV. Designed for standard blood work, the test identifies individuals who may have lung cancer, including early-stage disease, and aims to enhance population health by addressing the limited adoption of LDCT screening.

Which Companies Are Expanding Their Footprint In The Lung Cancer Diagnostic And Screening Market?

Major companies operating in the lung cancer diagnostic and screening market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Oncimmune Holdings Plc, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, OncoCyte, Broncus Medical Inc.

Read the full lung cancer diagnostic and screening market report here:

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Which Geographic Regions Are Influencing Demand In The Lung Cancer Diagnostic And Screening Market?

North America was the largest region in the lung cancer diagnostic and screening market in 2025. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Lung Cancer Diagnostic And Screening Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12043&type=smp

Browse Through More Reports Similar to the Global Lung Cancer Diagnostic And Screening Market 2026, By The Business Research Company

Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Respiratory Disease Testing Global Market Report

https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

Lung Cancer Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model